The reviewers added, “In large part, this is due to the inspirational leadership of Prof. Few years ago, his research group received the highest possible score by an international external review committee and was described as having a “world-leading position”. He is one of the inventors of “Radiomics” (quantitative imaging), Clinical Decision Support, “Medomics”, “Distributed learning” a revolutionary Big Data approach for health care. More recently, his interests have been directed towards Hypoxia Activated Prodrugs, during immunotherapy and the development of a “decision support system” based on multiparametric databases containing clinical, imaging, biological and therapeutic information, and taking into account patient preferences. ![]() His main areas of interest are directed towards translational research in Cancer Biology with a specific focus on tumour hypoxia, quantitative imaging (Radiomics), lung cancer and genetically engineered Clostridium as living medicine or factory able to produce biotherapeutics, vaccines and green energy. He is co-author of more than 616 peer reviewed scientific papers (>61K citations, Hirsch Index: 119 Google scholar, ), co-inventor of more than 22 patents (filed or submitted) of which 8 are in the (pre)commercialization phase and (co) promoter of more than 70 completed PhD’s. He has a PhD in Molecular Biology and is Professor at the University of Maastricht. ![]() Philippe Lambin is a Clinician-Scientist, Oncologist by training, “ERC advanced & ERC PoC (3x) grant laureate” and pioneer in translational research with a focus on Radiomics, AI-based Decision Support Systems, tumour hypoxia and living medicine.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |